Eli Lilly raises 2026 outlook again as Q2 soars past estimates

EarningsMounjaroPositive

AI Analysis

Summary

Eli Lilly reported Q2 earnings that exceeded estimates with Mounjaro achieving 91% growth, prompting the company to raise its 2026 outlook and widen its competitive lead over Novo Nordisk in the cardiometabolic market.

Financial Highlights

Guidance

2026 outlook raised

Outcome Details

Q2 earnings exceeded estimates with 91% Mounjaro growth; 2026 outlook raised

Importance:7/10

Sentiment:

0.80

earningsguidance_raiseMounjaromarket_leadershipcardiometabolic

Related Companies

$LLY

Read the original article

Published by Pharmaceutical Technology on August 6, 2026 10:18 AM

Read Original